Senhwa Biosciences Inc (生華科) aims to raise NT$1.5 billion (US$50.57 million) by issuing 15 million new common shares in the third quarter of this year to fund the research of new drugs, including the experimental drug Silmitasertib for the treatment of COVID-19, the company said on Monday.
That would be the firm’s largest fundraising effort after it raised more than NT$1.4 billion from an initial public offering on the Taipei Exchange (TPEX) in April 2017, chief financial officer Sarah Chang (張小萍) told the Taipei Times by telephone.
The price of the new shares would depend on the firm’s average share price over the five days before the secondary offering, Chang said. Companies usually offer discounts of up to 30 percent, she said.
As Senhwa Biosciences shares have stayed above NT$100 in the past few months, the company expects to raise at least NT$1.5 billion from the issuance of 15 million new shares, Chang said.
The fresh funds would fuel the company’s research and development of Silmitasertib, or CX-4945, which is a small-molecule drug for cancers, such as bile duct cancer, but has shown potential to combat the novel coronavirus with its capability to curb replication of the ribonucleic acid virus.
The company plans to test the drug on mice to evaluate its efficacy in cooperation with the US National Institutes of Health (NIH) next month, Senhwa Biosciences chief executive officer Soong Tai-sen (宋台生) said by telephone yesterday.
The preparation of the animal tests would take some time, as the mice first need to be genetically engineered to have a human version of a protein known as the angiotensin-converting enzyme 2 receptor, which the coronavirus uses as its point of entry, Soong said.
He expects the animal tests to be completed by the end of next month.
As conducting human tests with the experimental drug would be expensive, with an average cost of US$80,000 per subject, Senhwa Biosciences plans to apply to foreign agencies, such as the US Biomedical Advanced Research and Development Authority, for sponsorship, Soong said.
“Although the development of vaccines against COVID-19 is eye-catching, I think drugs will be the real solution for the pandemic, as COVID-19 antibodies might fade in less than two months, according to recent studies,” Soong said.
Senhwa Biosciences shares advanced 9.96 percent to NT$139.5 in Taipei trading yesterday, after an international team led by researchers at the University of California, San Francisco, identified Silmitasertib as one of the several drugs that could disrupt the viral takeover of cells.
The company’s shares have risen 120 percent from NT$63.5 in March, when the company began focusing on exploiting the experimental drug to treat COVID-19.
Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) has secured three construction permits for its plan to build a state-of-the-art A14 wafer fab in Taichung, and is likely to start construction soon, the Central Taiwan Science Park Bureau said yesterday. Speaking with CNA, Wang Chun-chieh (王俊傑), deputy director general of the science park bureau, said the world’s largest contract chipmaker has received three construction permits — one to build a fab to roll out sophisticated chips, another to build a central utility plant to provide water and electricity for the facility and the other to build three office buildings. With the three permits, TSMC
RUN IT BACK: A succesful first project working with hyperscalers to design chips encouraged MediaTek to start a second project, aiming to hit stride in 2028 MediaTek Inc (聯發科), the world’s biggest smartphone chip supplier, yesterday said it is engaging a second hyperscaler to help design artificial intelligence (AI) accelerators used in data centers following a similar project expected to generate revenue streams soon. The first AI accelerator project is to bring in US$1 billion revenue next year and several billion US dollars more in 2027, MediaTek chief executive officer Rick Tsai (蔡力行) told a virtual investor conference yesterday. The second AI accelerator project is expected to contribute to revenue beginning in 2028, Tsai said. MediaTek yesterday raised its revenue forecast for the global AI accelerator used
The DBS Foundation yesterday announced the launch of two flagship programs, “Silver Motion” and “Happier Caregiver, Healthier Seniors,” in partnership with CCILU Ltd, Hondao Senior Citizens’ Welfare Foundation and the Garden of Hope Foundation to help Taiwan face the challenges of a rapidly aging population. The foundation said it would invest S$4.91 million (US$3.8 million) over three years to foster inclusion and resilience in an aging society. “Aging may bring challenges, but it also brings opportunities. With many Asian markets rapidly becoming super-aged, the DBS Foundation is working with a regional ecosystem of like-minded partners across the private, public and people sectors
BREAKTHROUGH TECH: Powertech expects its fan-out PLP system to become mainstream, saying it can offer three-times greater production throughput Chip packaging service provider Powertech Technology Inc (力成科技) plans to more than double its capital expenditures next year to more than NT$40 billion (US$1.31 billion) as demand for its new panel-level packaging (PLP) technology, primarily used in chips for artificial intelligence (AI) applications, has greatly exceeded what it can supply. A significant portion of the budget, about US$1 billion, would be earmarked for fan-out PLP technology, Powertech told investors yesterday. Its heavy investment in fan-out PLP technology over the past 10 years is expected to bear fruit in 2027 after the technology enters volume production, it said, adding that the tech would
RSS